In preclinical studies, XV Technology has been used extensively to examine regional ventilation in disease models for Cystic Fibrosis, Acute Respiratory Distress Syndrome, chronic lung allograft dysfunction, Alpha-1 antitrypsin deficiency, and Lymphangioleiomyomatosis.